<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00326287</url>
  </required_header>
  <id_info>
    <org_study_id>CR011407</org_study_id>
    <secondary_id>30982081-CAP-3001</secondary_id>
    <nct_id>NCT00326287</nct_id>
  </id_info>
  <brief_title>Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia</brief_title>
  <official_title>A Randomized, Double-Blind, Multicenter Study of Ceftobiprole Medocaril Versus Placebo in the Treatment of Subjects Hospitalized With Community-Acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical cure rate (ratio of clinically cured
      patients to the total number of patients) of ceftobiprole medocaril versus a comparator in
      the treatment of patients with community-acquired pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ceftobiprole medocaril is a cephalosporin antibiotic with anti-MRSA (Methicillin-Resistant
      Staphylococcus Aureus) activity. Ceftobiprole medocaril is not yet approved for the treatment
      of community-acquired pneumonia. This is a randomized, double-blind, multicenter study of
      ceftobiprole medocaril plus placebo versus a comparator to assess the effectiveness and
      safety of ceftobiprole medocaril in patients with community-acquired pneumonia. The patients
      will be randomized to ceftobiprole medocaril plus placebo or a comparator. Patients who meet
      specified criteria may be switched to an alternative oral treatment. The primary endpoint is
      that the clinical cure rate among patients treated with ceftobiprole at the test of cure
      visit. The patients will receive either ceftobiprole medocaril plus placebo or a comparator.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure rate (ratio of the number of clinically cured patients to the total number of patients) at the test of cure visit that occurs 7 to 14 days after the last dose of study drug</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological eradication rate (ratio of the number of patients with microbiological eradication to the total number of patients)</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">638</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Ceftobiprole medocaril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftriaxone with or without Linezolid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ceftriaxone 2g qd as 0.5h infusions with or without Linezolid 600mg q12h as 1h infusions, 7-14d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftobiprole medocaril</intervention_name>
    <arm_group_label>Ceftobiprole medocaril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone with or without Linezolid</intervention_name>
    <arm_group_label>Ceftriaxone with or without Linezolid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from community-acquired pneumonia severe enough to require
             hospitalization

          -  Female patients must be postmenopausal for at least 1 year, surgically sterile, or
             practicing an effective method of birth control before entry and throughout the study

        Exclusion Criteria:

          -  Patients with known or suspected hypersensitivity to any related antibiotic
             medications

          -  Treatment with any experimental drug within 30 days before enrollment

          -  Prior enrollment in this study or any study with ceftobiprole medocaril
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>China</country>
    <country>Costa Rica</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=731&amp;filename=CR011407_CSR.pdf.pdf</url>
    <description>Ceftobiprole in the Treatment of Patients with Community-Acquired Pneumonia</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2006</study_first_submitted>
  <study_first_submitted_qc>May 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2006</study_first_posted>
  <disposition_first_submitted>June 3, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 3, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 16, 2011</disposition_first_posted>
  <last_update_submitted>July 25, 2012</last_update_submitted>
  <last_update_submitted_qc>July 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Community-Acquired Pneumonia</keyword>
  <keyword>Cephalosporins</keyword>
  <keyword>Methicillin-Resistant Staphylococcus Aureus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Ceftobiprole</mesh_term>
    <mesh_term>Ceftobiprole medocaril</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

